Clinical Trial Update: Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety and immunogenicity of LEISH-F2 + MPL-SE vaccine with SSG in patients with post-kala-azar dermal leishmaniasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-kala-azar Dermal Leishmaniasis

Drugs mentioned

• LEISH-F2 + MPL-SE vaccine with SSG (LEISH-F2 vaccine with MPL-SE adjuvant plus sodium stibogluconate)
• Sodium stibogluconate (sodium stibogluconate)

Snippet

Sponsor: Access to Advanced Health Institute (AAHI) | Conditions: Post Kala Azar Dermal Leishmaniasis | Phase 1 | Status: COMPLETED